Lexicon Pharmaceuticals (NASDAQ:LXRX) released findings from two separate Phase I trials this morning for Rheumatoid Arthritis and glaucoma. LX2931 was studied for its safety and tolerability in ten RA patients, with efficacy as a second endpoint. Patients had no major adverse events and even showed some improvement in disease symptoms; the company hopes to advance the product into Phase II to test its efficacy as an RA treatment. In the second of the two Phase 1’s, patients underwent treatment for glaucoma, given as an eye drop with Lexicon’s LX7101. Again, the study proved safety, at tested doses, was not an issue. Lexicon says they will be conducting further evaluation and discussing opportunities with potential partners before moving forward with Phase 2 trials. Shares are up 2% already this morning and should continue to rise as the RA data has been expected for some time.